Can healthcare recover from 'Medicare for the masses'?



​A proposal to expand Medicare and eliminate private insurance in the US pummelled healthcare stocks recently. Andy Acker, Portfolio Manager, and Rich Carney, Research Analyst on the Global Life Sciences Team, explain what it means for investors.

It’s been a tough few weeks for healthcare stocks. On April 10, Senator Bernie Sanders, a Democratic candidate in the 2020 US presidential race, introduced legislation for a Medicare-for-all health insurance scheme. Under the plan, private insurance in the US would be eliminated and Medicare, the federal health insurance programme for those aged 65 and older, would be expanded to all Americans.

Not surprisingly, managed care stocks plummeted, falling roughly 10% from 10 April to 18 April. The carnage also spread to other sub-sectors, including biotechnology and pharmaceuticals, which declined 7% and 4%, respectively, for the same period. All told, the healthcare sector was flat year to 18 April, compared with a more than 16% total return for the S&P 500 Index (Source: Bloomberg, as at 18 April 2019. Returns in US dollar terms).

Taking stock of the sell off

Understandably, investors may be worried about what’s next for healthcare. The Medicare-for-all proposal is not the first single-payer health plan ever put forth in the US, but Sanders is currently a front-runner for the Democratic nomination, and the bill was co-sponsored by other prominent Democratic candidates, including Senators Kirsten Gillibrand, Elizabeth Warren and Cory Booker, suggesting healthcare reform could remain a focal point for the next 12 to 18 months of the election cycle. In addition, UnitedHealth Group, one of the largest private insurers in the US, used April’s quarterly earnings call to address the proposal, which only seemed to spook investors more.

However, we believe the odds are low that Medicare-for-all could become a reality in the US, for a number of key reasons:

Lack of bipartisan support: Despite some candidates’ zeal for the proposal, key Democratic leaders in the House and Senate have been reluctant to back it, including House Speaker Nancy Pelosi, who has said she prefers trying to improve the Affordable Care Act. Meanwhile, managed care companies have significant lobbying power and deep pockets with which to fight the legislation.

Substantial costs: The cost of moving to a single-payer healthcare system in the US is unknown at this point. Some estimates suggest total healthcare spending as a percentage of GDP could potentially rise by trillions of dollars over the next 10 years, depending on how benefits are designed and payment rates to hospitals and other providers are determined. Other estimates suggest costs would actually fall.

Benefit design and payment rates are critical issues. Today, payments by private insurance plans to hospitals and other providers help subsidise lower rates negotiated by Medicare. If providers had to accept Medicare-level rates for all services, many practitioners might be forced to accept lower incomes or be laid off, and a number of hospitals – the vast majority of which are nonprofit – would likely shut overnight.

Meanwhile, although Medicare is a highly valued public scheme, it is not without its shortcomings. Notably, the trust fund covering inpatient hospital services for Medicare is projected to start running out of money in 2026. In order to replenish and expand the fund, payroll taxes would have to rise significantly or patient benefits be reduced.

Consumer unease: With the passage of the Affordable Care Act, we learned that most consumers do not want to jeopardise existing healthcare benefits or relationships with practitioners. More than eight in 10 Americans already receive coverage through either an employer, Medicaid or Medicare, according to the Kaiser Family Foundation. Upending that system would be highly disruptive and likely face substantial pushback.

What it means for investors

All said, we believe the odds of Medicare-for-all passing are extremely low (likely less than 5%). However, healthcare stocks initially reacted as though the probability was as high as 20% to 30% (The sector has since retraced some losses.) In our opinion, this discrepancy has made valuations for many stocks within the sector attractive. In fact, many firms that we view as high quality and that we think have significant growth potential now trade at substantial discounts to the market.

More importantly, we believe managed care fundamentals remain sound. In recent years, plan providers have been able to expand market share by building out integrated services with the help of technology, delivering value to patients while also reducing costs. Such initiatives have led to steady revenue growth for many insurance providers, which in turn has fuelled dividend growth, share repurchases and positive stock performance.

At the same time, we believe the healthcare sector as a whole is in a period of unprecedented innovation, driven by a greater understanding of the human genome and new modalities for treating human disease, from antibodies to gene-based therapies. Within medical technology, new devices can now repair faulty heart valves without the need for open-heart surgery and robots are increasingly enabling minimally invasive surgeries with more precision than ever before. Last year, the US Food and Drug Administration approved 59 novel therapies – the most ever in a calendar year – and we expect further exciting drug approvals in 2019.

Unfortunately, uncertainty around healthcare reform could, in the near term, do more to drive the sector’s performance than fundamentals. We think investors should prepare for heightened volatility. But we also believe there are ways to minimise the swings by focussing on companies developing innovative medicines that meet high, unmet medical needs. Therapies that markedly improve the current standard of care are likely to receive reimbursement regardless of the political backdrop. In addition, some companies fall outside the insurance debate, including those that generate significant revenues outside the US, firms that manufacture cash-pay products, such as contact lenses or cosmetic treatments, and those in the animal health industry.

Focus on the long term

We firmly believe that private insurance will not disappear in the US. However, we think some reforms are likely. Already, the Trump administration has unveiled regulation for Medicare that would require drug manufacturers to share rebates with seniors at the point of sale rather than the current system, in which savings are passed on to pharmacy benefit managers, distributors and other members of the drug supply chain. The administration is also considering a proposal that would require prices negotiated between hospitals and health plans to be made public. In the long run, we believe such initiatives could bring much-needed transparency to a system fraught with complexity and high costs and that rightly has drawn the ire of consumers. And against this backdrop, we believe companies levered to such reforms – whether by focusing on innovation, improving efficiencies, lowering costs or expanding access to medical care – could be well positioned.


These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

For promotional purposes.

Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Global Life Sciences Fund

For institutional/ sophisticated investors / accredited investors qualified distributors use only.

All content in this document is for information or general use only and is not specific to any individual client requirements. The information contained in this document is referential and may not be construed as an offer, invitation or recommendation or investment advice, nor should be taken as a basis to take (or stop taking) any decision.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons.  Past performance is not indicative of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements.  Shares, if redeemed, may be worth more or less than their original cost.

Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this document and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. As with all investments, there are inherent risks that each individual should address.

The distribution of this document or the information contained in it may be restricted by law and may not be used in any jurisdiction or any circumstances in which its use would be unlawful.

Issued in Europe by Janus Capital International Limited (“JCIL”), authorised and regulated by the U.K. Financial Conduct Authority. Janus Capital International Limited (“JCIL”) is an entity registered and operating under the laws of the United Kingdom and Janus Capital Funds plc. is registered under the legislation of Ireland.

The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd (“FIFS”), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l’Ile, CH-1204 Geneva. The last share prices can be found on For Qualified investors, institutional, wholesale client use only. Outside of Switzerland, this document is for professional use only. Not for onward distribution.

This material is strictly private and confidential and may not be reproduced or used for any purpose other than evaluation of a potential investment in Janus Capital International Limited’s products or the procurement of its services by the recipient of this presentation or provided to any person or entity other than the recipient of this presentation.

We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Janus Capital Management LLC serves as investment adviser. Janus, Intech and Perkins are registered trademarks of Janus International Holding LLC. © Janus International Holding LLC. For more information or to locate your country’s Janus representative contact information, please visit

Specific risks

  • This fund is designed to be used only as one component of several in a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested into this fund.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.

Risk rating

Janus Henderson Horizon Biotechnology Fund

This document is intended solely for the use of professionals and is not for general public distribution.

The Janus Henderson Horizon Fund (the “Fund”) is a Luxembourg SICAV incorporated on 30 May 1985, managed by Henderson Management S.A. Any investment application will be made solely on the basis of the information contained in the Fund’s prospectus (including all relevant covering documents), which will contain investment restrictions. This document is intended as a summary only and potential investors must read the Fund’s prospectus and key investor information document before investing. A copy of the Fund’s prospectus and key investor information document can be obtained from Henderson Global Investors Limited in its capacity as Investment Manager and Distributor.

Issued in Europe by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Capital International Limited (reg no. 3594615), Henderson Global Investors Limited (reg. no. 906355), Henderson Investment Funds Limited (reg. no. 2678531), AlphaGen Capital Limited (reg. no. 962757), Henderson Equity Partners Limited (reg. no.2606646), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Henderson Management S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier). We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Past performance is not a guide to future performance. The performance data does not take into account the commissions and costs incurred on the issue and redemption of units. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor’s particular circumstances and may change if those circumstances or the law change. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially.

Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment.

The Fund is a recognised collective investment scheme for the purpose of promotion into the United Kingdom. Potential investors in the United Kingdom are advised that all, or most, of the protections afforded by the United Kingdom regulatory system will not apply to an investment in the Fund and that compensation will not be available under the United Kingdom Financial Services Compensation Scheme.

Copies of the Fund’s prospectus and key investor information document are available in English, French, German, and Italian. Articles of incorporation, annual and semi-annual reports are available in English. Key Investor document is also available in Spanish. All of these documents can be obtained free of cost from the local offices of Janus Henderson Investors: 201 Bishopsgate, London, EC2M 3AE for UK, Swedish and Scandinavian investors; Via Dante 14, 20121 Milan, Italy, for Italian investors and Roemer Visscherstraat 43-45, 1054 EW Amsterdam, the Netherlands. for Dutch investors; and the Fund’s: Austrian Paying Agent Raiffeisen Bank International AG, Am Stadtpark 9, A-1030 Vienna; French Paying Agent BNP Paribas Securities Services, 3, rue d’Antin, F-75002 Paris; German Information Agent Marcard, Stein & Co, Ballindamm 36, 20095 Hamburg; Belgian Financial Service Provider CACEIS Belgium S.A., Avenue du Port 86 C b320, B-1000 Brussels; Spanish Representative Allfunds Bank S.A. Estafeta, 6 Complejo Plaza de la Fuente, La Moraleja, Alcobendas 28109 Madrid; Singapore Representative Janus Henderson Investors (Singapore) Limited, 138 Market Street, #34-03 / 04 CapitaGreen 048946; or Swiss Representative BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich who are also the Swiss Paying Agent. RBC Investor Services Trust Hong Kong Limited, a subsidiary of the joint venture UK holding company RBC Investor Services Limited, 51/F Central Plaza, 18 Harbour Road, Wanchai, Hong Kong, Tel: +852 2978 5656 is the Fund’s Representative in Hong Kong.

Information on this document is on Janus Henderson Investors’ best endeavours.

Specific risks

  • The Fund could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Fund.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Changes in currency exchange rates may cause the value of your investment and any income from it to rise or fall.
  • If the Fund or a specific share class of the Fund seeks to reduce risks (such as exchange rate movements), the measures designed to do so may be ineffective, unavailable or detrimental.
  • The Fund's value may fall where it has concentrated exposure to a particular industry that is heavily affected by an adverse event.
  • Any security could become hard to value or to sell at a desired time and price, increasing the risk of investment losses.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.

Risk rating


Important message